VANCOUVER, June 4 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company announces that it has received a Health Canada license for a next-generation multi-purpose laser system that is suitable for a broad range of applications in high volume settings, such as hospitals and large institutions. This system will initially be directed towards decolonization of potentially pathogenic bacteria such as S. aureus and MRSA in the nose, as well as for the decolonization of microorganisms from other sites.

Photodisinfection utilizes photoactive agents and light sources to effect potent, broad-spectrum disinfection across a variety of dental, medical and other applications. The Company's photodisinfection laser is expected to provide an alternative resource to antibiotics for clinicians and patients in the eradication of S. aureus and resistant 'superbugs' including MRSA. According to the Centers for Disease Control and Prevention (CDC), antibiotic resistance has become 'one of the world's most pressing public health problems'.

"With rates of hospital-acquired infections and antibiotic resistance rising steeply, it is imperative that non-antibiotic, anti-infective therapies are developed," stated Carolyn Cross, Ondine's President and CEO. "Many hundreds of clinicians in Canada and the European Union are successfully using our Periowave(TM) photodisinfection technology for the treatment of periodontal disease. We believe that this technology may be capable of addressing many other clinically unmet needs where a broad-spectrum, safe, non-antibiotic therapy is required. We intend to commercialize additional applications of our versatile photodisinfection platform through strategic partners, leveraging in-house expertise in rapid product development, regulatory affairs and existing sales and marketing channels."